Jump to main content
eTG Complete
eTG Complete
Index
  1. Home
  2. Antibiotic
  3. Directed therapy for pneumonia
  4. Pneumocystis jirovecii pneumonia (PJP)
  5. Treatment of high-severity Pneumocystis jirovecii pneumonia (PJP)
  6. Approach to managing high-severity PJP
  • Antibiotic
    • Bartonella infections
    • Osteomyelitis
    • Septic arthritis of a native joint
    • Bone and joint infections other than osteomyelitis and native joint septic arthritis
    • Sepsis or septic shock associated with a bone or joint source
    • Directed therapy for native bone or joint infection
    • Brucellosis
    • Infective endocarditis
    • Cardiovascular system infections other than endocarditis
    • Central nervous system infections
    • Coronavirus disease 2019 (COVID-19)
    • Cryptococcosis
    • Cytomegalovirus (CMV) infection
    • Infectious diarrhoea
    • Ear, nose and throat infections
    • Eye infections
    • Febrile neutropenia
    • Genital and sexually transmissible infections
    • Human immunodeficiency virus
    • Intra-abdominal infections
    • Leptospirosis
    • Lyme disease
    • Mediastinitis
    • Melioidosis
    • Mpox (monkeypox)
    • Nocardiosis
    • Nontuberculous mycobacterial infections
    • Oesophageal infections
    • Parasitic infections
    • Perinatal infections
    • Prevention of infection
    • Q fever
    • Pneumonia
    • Directed therapy for pneumonia
      • Directed therapy for pneumonia
      • Acinetobacter baumannii pneumonia in adults
      • Enterobacterales pneumonia
      • Haemophilus influenzae pneumonia
      • Legionella pneumonia in adults
      • Mycoplasma pneumoniae pneumonia and Chlamydophila (Chlamydia) species pneumonia
      • Pseudomonas aeruginosa pneumonia
      • Staphylococcus aureus (staphylococcal) pneumonia
      • Stenotrophomonas maltophilia pneumonia
      • Streptococcus pneumoniae (pneumococcal) pneumonia
      • Overview of fungal pneumonia
      • Aspergillosis
      • Pneumocystis jirovecii pneumonia (PJP)
        • Overview of Pneumocystis jirovecii pneumonia (PJP)
        • Assessment of Pneumocystis jirovecii pneumonia (PJP) disease severity
        • Treatment of low- to moderate-severity Pneumocystis jirovecii pneumonia (PJP)
        • Treatment of high-severity Pneumocystis jirovecii pneumonia (PJP)
          • Approach to managing high-severity PJP
          • Preferred antimicrobial therapy for high-severity PJP
          • Treatment for high-severity PJP in patients with hypersensitivity to trimethoprim+sulfamethoxazole
          • Corticosteroid therapy for high-severity PJP
        • Maintenance therapy for Pneumocystis jirovecii pneumonia (PJP)
        • References
    • Respiratory tract infections other than pneumonia
    • Acute rheumatic fever
    • Rickettsial infections
    • Salivary gland infections
    • Sepsis and septic shock: Identification and initial management
    • Sepsis and septic shock: Empirical regimens
    • Directed therapy for bloodstream infections, including sepsis and septic shock
    • Skin and soft tissue infections
    • Traumatic wound infections
    • Urinary tract infections in adults
    • Urinary tract infections in children
    • Identifying resistant pathogens or Candida species
    • Principles of obtaining blood for culture
    • Principles of antimicrobial use
    • Antimicrobial stewardship (AMS)
    • Practical information on using antimicrobial drugs
    • Aminoglycoside use
    • Vancomycin use in adults
    • Vancomycin use in young infants and children
    • Monitoring antimicrobial blood concentrations
    • Ambulatory antimicrobial therapy
    • Antimicrobial hypersensitivity
    • Kidney impairment and antimicrobial dosing
    • Contact details for health departments and public health units
    • Amikacin initial dose calculator
    • Gentamicin initial dose calculator
    • Tobramycin initial dose calculator

Approach to managing high-severity PJP

To manage a patient with high-severity Pneumocystis jirovecii pneumonia (PJP):

  • prescribe antimicrobial therapy
  • consider if adjunctive corticosteroid therapy is required
  • consider if maintenance therapy (secondary prophylaxis) for PJP is indicated.
  • Contact us
  • Conditions of use and disclaimer
  • Privacy policy
  • Copyright permission
  • Support and FAQ

www.tg.org.au
All site content © Therapeutic Guidelines Limited 2020. Therapeutic Guidelines Limited, Ground Floor, 473 Victoria Street, West Melbourne, Victoria 3003, Australia © Therapeutic Guidelines Ltd (eTG August 2020)

Created: No created attribute found. Modified: No revised attribute found. (HW Diagnostics)